GDBspace, a Space Pharmaceuticals company, selected among 10 Swiss scale-up companies to join the Venture Kick Scale Up Bootcamp
GDBspace, a Space Pharmaceuticals company specialized in computational methods for drug discovery, was selected by the Venture Kick jury, to join the Venture Kick Scale Up Bootcamp among 10 Swiss scale-up companies.
The Swiss companies selected are: Lino Biotech, Galventa, Alithea Genomics, Resistell, Oncobit, Healiva, GDBspace, FluoSphera, Recolony and Alithea Genomics.
Dr. Jingwen Shi, CBO at Space Pharmaceuticals said “We are really glad to be part of the Venture Kick Scale Up Bootcamp! This is a very good platform to connect with large corporates for business development, and everyone from large corporates was very curious and eager to discuss at this exclusive bootcamp”.
We are pleased to welcome Dr. Kapila Gunasekera as Senior Computational Chemist. Dr. Gunasekera is a molecular biology and computational biology scientist with experience spanning from biology to genetics, bioinformatics and peptide chemistry, as well as a track records of excellent publications. At GDBspace, Dr. Kapila Gunasekera will work on computational peptide design.
Space Pharmaceuticals, an AI-driven chemical space drug discovery company based in Basel, Switzerland, announced the completion of a Series A financing round of CHF 12 million, led by Venture Capital firm Cowin Capital.
Spinned-off from 20 years of computational chemistry research from Prof. Jean-Louis Reymond, University of Bern, Switzerland, Space Pharmaceuticals’ GDBspace drug discovery engine has a unique approach to the design of the largest and most diverse small molecule (incl. peptides and peptidomimetics) library till date, mapped with molecular fingerprints to decode this chemical space. A portfolio of Artificial Intelligence (AI)-augmented technologies and state-of-the-art algorithms, empower the evaluation of billions of molecules to design drugs faster and cheaper. The Space Peptides laboratory arm is specialized in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests.
Dr. Runze He, CEO of Space Pharmaceuticals says: “The confidence of our investors together with successful partnerships with established pharma and biotech companies further validates our AI-driven discovery platform to de-risk drug discovery programs, increase success rates, and significantly reducing time and costs. With some of the first AI-designed drugs entering the clinic, we are convinced of the value of AI in de-risking and transforming the pharmacoeconomics of drug discovery.”
About Space Pharmaceuticals
Space Pharmaceuticals AG (“Space Pharmaceuticals”) is an AI-based drug discovery and peptide manufacture company. Its proprietary GDBspace discovery engine applies chemical space-based drug discovery, combined with artificial intelligence, to identify small molecules (incl. peptides and peptidomimetics) of interests in a precise and time-efficient manner –
hence de-risking projects, increasing success rates, and significantly reducing time and costs. The Space Peptides laboratory arm is specialized in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests. For more information, please visit Space Pharmaceutical’s website at www.gdbspace.com, www.spacepeptides.com
Space Pharmaceuticals is pleased to welcome Dr. Simon Nebel as Business Advisor.
Dr. Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions for Aravis portfolio companies. He has been the board member or observer in fourteen companies. Before joining Aravis, he was a group strategist at UBS. Dr. Nebel got his PhD in Biophysics at the Biocentre of the University of Basel and an MBA from the London Business School.